Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002446
Abstract: Background Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, we report the phase 1 data from…
read more here.
Keywords:
probody;
pacmilimab;
solid tumors;
pacmilimab ipilimumab ... See more keywords